MTNB earnings

BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available o

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be available on the IR Ca

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today

Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data from prior in vivo study of oral LNC-docetaxel showing reductions in tumor size comparable to IV-docetaxel Management to host to 2023 Financial Results and Business Update Conference Call on March 27, 2024 BEDMINSTER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces positive result

BEDMINSTER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report third quarter 2023 financial results after market close on Wednesday, November 8, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call, please dial 800-267-6316 (Toll-Free) or 203-518-9783 (Toll). The webc

FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality non-inferiority margin of 10% FDA provided alternative trial designs which include the highest-need patients, aligning with growing positive treatment success in Matinas' Compassionate/Expanded Use Program as highlighted by a recent case update from Nationwide Children's Hospital Internal RNAi programs demonstrate compelling in vitro activity; in vivo studies evaluating biological activity of LNC oral formulations of small oligonucleotides expected in second half of 2023 Conference call begins at 4:30 p

BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report second quarter 2023 financial results after market close on Wednesday, August 9, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The

FDA feedback from Type B meeting reiterated the Agency's intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial design is being finalized to support a broad label for IFIs under a 505(b)(2) regulatory pathway Initial in vivo study of oral mRNA delivery did not demonstrate preclinical activity; research under the collaboration agreement with BioNTech has been concluded Successful in vivo systemic delivery and activity of mRNA in multiple additional studies Conference call begins at 4:30 p.m. Eastern time today BEDMINSTER, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stag

BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be av

Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting expected to impact partnership discussions and facilitate potential non-dilutive BARDA and/or NIH funding Conference call and webcast begin at 4:30 p.m. Eastern time today BEDMINSTER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2022 financial results and provides a business update. "

BEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report 2022 financial results after market close on Wednesday, March 15, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be available on

2022 Success Has Increased Confidence to Focus LNC Delivery Platform on the Future of Medicine - Delivering Genes Prioritization on Building External Partnerships and an Internal Pipeline Centered on Gene Therapies and Nucleic Acids Collaborations with BioNTech (mRNA Partner) and National Resilience (Nucleic Acid Platform Partner) Expected to Generate Initial In Vivo Data in 1H 2023 Seeking BARDA Financial Support and FDA Feedback on Phase 3 Study in Invasive Fungal Infections of MAT2203 Prior to Commencing Phase 3 Program Ended 2022 with Approximately $28.8 Million, Sufficient to Fund Planned Operations into Q2 2024 Conference Call and Live Audio Webcast Scheduled Today, Jan

BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced that the Company will host a conference call and live audio webcast on Monday, January 30, 2023 at 4:30 p.m. ET to provide a corporate update and discuss the Company's business outlook for 2023. During the call, senior management will provide updates on the Company's ongoing programs, including third party collaborations. To participate in the call, please dial (877) 407-5976 or (412)-902-0031. The live we

EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen Phase 3 pivotal trial of MAT2203 for treatment of cryptococcal meningitis to commence Q1 2023 The Infectious Diseases Society of America (IDSA) chose EnACT as its Outstanding Abstract and IDSA Awardee at IDWeek 2022 Eric J. Ende, MD, MBA appointed as Chairman of the Board effective October 1, 2022, with founding Chairman Herbert J. Conrad remaining as an Independent Director $33.1 million in cash, cash equivalents, and marketable securities at September 30, 2022, sufficient to fund planned operations through 2023 Management to Host Confer

BEDMINSTER, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced the company will host a conference call and live audio webcast on Wednesday, November 2, 2022 at 4:30 p.m. ET to discuss operational and financial results for the third quarter ended September 31, 2022. To participate in the call, please dial 888-609-1607 (Toll-Free) or (862) 298-0702 (Toll). The live webcast will be accessible on the Investors section of Matinas' website, www.matina

75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility and Clarity on Phase 3 Program and Single Pivotal Registration Trial for MAT2203 in Cryptococcal Meningitis; Trial Expected to Commence Q1 2023 Initial Scientific Advice and Positive Opinion on Orphan Drug Designation from EMA Provide Global Regulatory Alignment for MAT2203 in Key Commercial Regions Company Remains in Discussions with BioNTech for Option to License the LNC Platform for mRNA on an Exclusive Basis $38.5 million at June 30, 2022, Sufficient to Fund Planned Operations Through 2023 Management to Host Conference Call Today,

BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced the Company will host a conference call and live audio webcast on Thursday, August 11, 2022 at 8:30 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2022. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13730276. The live webcast will be accessible on the Investors section of Mati

– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas' proprietary LNC platform technology – – 50% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data Expected Q3 2022 – – Feedback from Clinical Type C Meeting with the FDA Provides Potential Pathway to NDA Submission for MAT2203 with a Single Confirmatory Trial for Both Induction and Consolidation Indications – – Successful Second In Vivo Efficacy Study of Oral LNC-Remdesivir – –$43.9 million at March 31, 2022, Sufficient to Fund Planned Operations Through 2023 – – Management to Host C

BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced the Company will host a conference call and live audio webcast on Thursday, May 12, 2022 at 8:30 a.m. ET to discuss operational and financial results for the first quarter ended March 31, 2022. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13727955. The live webcast will be accessible on the Investors section of Matinas

– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data to Come from Cohort 5 of EnACT Trial – – Second in vivo Study of Oral LNC-remdesivir to Commence in March 2022 – – Moving Aggressively into Nucleic Acids with Internal Discovery Programs Initiated with mRNA, DNA and Antisense Oligonucleotides (ASOs) – – $49.6 million at Year-End 2021, Sufficient to Fund Planned Operations Through 2023 – – Management to Host Conference Call Today, Tuesday, March 8th, at 8:30 a.m. ET – BEDMINSTER, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma

BEDMINSTER, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced the Company will host a conference call and live audio webcast on Tuesday, March 8, 2022 at 8:30 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2021. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13727084. The live webcast will be accessible on the Investo

– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of EnACT (all oral induction regimen) Underway With Six Patients Enrolled and Topline Interim Data Expected Q3 2022 – – In Vivo Study of Orally Administered LNC Remdesivir Demonstrated Reduced Viral Titers and Effects Similar to Subcutaneous Administered Remdesivir; NIAID to Support an Additional Preclinical Study – – Ended 2021 with $49.9 Million, Sufficient to Fund Planned Operations Through 2023 – – Conference Call and Live Audio Webcast Scheduled Today, January 25th at 8:30 a.m. ET – BEDMINS

BEDMINSTER, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced that the Company will host a conference call and live audio webcast on Tuesday, January 25, 2022 at 8:30 a.m. ET to provide a corporate update and discuss the Company's business outlook for 2022. During the call, senior management will provide updates on each of the Company's ongoing programs, including third party collaborations. To participate in the call, please dial (877) 407-5976 (Toll-

– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recommended progression to second half of study – – Dosing initiated in Phase 1 study of potential first oral aminoglycoside antibiotic drug MAT2501 (oral amikacin) – – Accomplished biotechnology executive, Kathryn Penkus Corzo, joined Company's Board of Directors – – Management to host conference call today, Monday, November 8th, at 8:30 a.m. ET – BEDMINSTER, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company 

BEDMINSTER, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Monday, November 8, 2021 at 8:30 a.m. ET to discuss operational and financial results for the third quarter ended September 30, 2021. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13723555. The live webcast will be accessible on the Investor

– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.20 – – Overall survival was >95% in 40 patients receiving MAT2203 in Cohort 2 – – All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first 10 weeks of antifungal treatment – – Patients received MAT2203 for up to 6 weeks without kidney toxicity or electrolyte abnormalities attributable to MAT2203 – – DSMB unanimously recommends progression to Cohort 3; Enrollment has commenced – – Preparing to engage with FD

– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second cohort anticipated September 2021 – – Positive recent FDA feedback on MAT2501 (oral amikacin) development program allows for initiation of Phase 1 study in healthy volunteers in Q4 2021 – – In vitro studies of lipid nanocrystal (LNC) formulations of Gilead Sciences' remdesivir demonstrate meaningful efficacy compared to free remdesivir, with a favorable toxicity profile; National Institute of Allergy and Infectious Diseases (NIAID) preparing to initiate an in vivo efficacy study of LNC-remde

BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET to discuss operational and financial results for the second quarter ended June 30, 2021. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and reference conference ID 13720567. The live webcast will be accessible on the Investors sect